Dana-Farber Cancer Institute: Immunotherapy Combination Shows Significant Benefit for Patients With Advanced Melanoma
January 07, 2022
January 07, 2022
BOSTON, Jan. 7 (TNSJou) -- The Dana-Farber Cancer Institute issued the following news release:
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. The trial, known as the RELATIVITY-047 study was co-led by Dana-Farber Cancer Institute investigators and the results were reported today in the New England Journal of Medicine . . .
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. The trial, known as the RELATIVITY-047 study was co-led by Dana-Farber Cancer Institute investigators and the results were reported today in the New England Journal of Medicine . . .